Related Experiment Video
Updated: Mar 8, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies
Vasanthakumar Sekar1, Debapriya Ghosh Mehrotra2, Biswanath Majumder2
1Department of Cancer Biology, Mitra Biotech, 202, Narayana Nethralaya, Health City, Hosur Main Road, Bangalore, 560099 India.
Abstract:
Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies.
Insights
Precision oncology advances molecular diagnostics for urological cancers like prostate, bladder, and renal tumors. This review highlights new platforms for personalized treatment and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Diagnostics
- Urological Malignancies
Background:
- Urological cancers (prostate, bladder, renal) are major causes of cancer mortality globally.
- Current treatments show limited response rates for primary and advanced stages.
- There's a need for patient-driven diagnostic and therapeutic strategies.
Purpose of the Study:
- To review recent advancements in molecular diagnostics and functional testing for urological malignancies.
- To explore the application of these technologies in precision oncology.
- To identify potential biomarkers for toxicity risk and treatment response prediction.
Main Methods:
- Review of current literature on molecular diagnostics and functional testing platforms.
- Analysis of precision oncology approaches in urological cancer care.
- Focus on patient-driven profiling and tumor microenvironment insights.
Main Results:
- Emerging molecular diagnostic tools offer deeper insights into tumor complexity.
- Functional testing platforms are being developed for personalized treatment strategies.
- Biomarker discovery is crucial for predicting treatment response and toxicity.
Conclusions:
- Molecular diagnostics and functional testing are pivotal for advancing precision oncology in urological cancers.
- These approaches can enhance clinical decision-making for tailored patient management.
- Further research is needed to fully integrate these innovations into routine clinical practice.
